Rapid desensitization for brentuximab vedotin (Adceteris(®)) allergy: a case report

BACKGROUND: Brentuximab vedotin (BV) is an antibody–drug conjugate formed by an anti-CD30 chimeric IgG(1) conjugated with monomethyl-auristatin-E. BV targets the CD30(+) cells, which characterize Hodgkin lymphoma as well as anaplastic large cell lymphoma. Once bound to the CD30(+) cells BV exerts it...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Girolamo, Attilio, Albanesi, Marcello, Sinisi, Alessandro, Nettis, Eustachio, Di Bona, Danilo, Caiaffa, Maria Filomena, Macchia, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205792/
https://www.ncbi.nlm.nih.gov/pubmed/30386181
http://dx.doi.org/10.1186/s12948-018-0100-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205792/
https://www.ncbi.nlm.nih.gov/pubmed/30386181
http://dx.doi.org/10.1186/s12948-018-0100-0

Ejemplares similares